We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 31

Expert opinion as to what “one would expect” is speculation, not evidence

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice

What to expect when you are expecting to launch a drug in Canada regulatory overview

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 2 2015

This article provides a brief overview of key regulatory issues to be aware of when marketing a drug in Canada. Price Regulation and Reimbursement

Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of

Sanofi-Aventis, et al. V. Apotex Inc., et al.

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • November 10 2014

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis

“Gene Patent” controversy comes to Canada

  • Bereskin & Parr LLP
  • -
  • Canada, USA
  • -
  • November 4 2014

Patents related to isolated DNA corresponding to a gene, as well as methods claiming the diagnostic use of such DNA sequences are often referred to

USPTO issues new subject matter guidance post-Myriad and Prometheus

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in

The Supreme Court of Canada grants leave to appeal in the Plavix case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 30 2014

The Supreme Court of Canada announced today that it has granted leave to appeal to Apotex Inc. from the Federal Court of Appeal (FCA) in the patent

Summary judgment for impeachment action of Viagra patent upheld by FCA

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 24 2014

On January 22, 2014 the Federal Court of Appeal ("FCA") in Pfizer Ireland Pharmaceuticals v Apotex Inc, dismissed an appeal from the judgment of the

Federal court considers “functionally” - limited claims in a biologic case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 22 2014

The Federal Court of Canada recently issued a decision in AbbVie Corporation v. Janssen Inc.,2014 FC 55, involving infringement and validity of a